Hepatitis C Virus (HCV) across the NHBS Populations

As part of the National HIV Behavioral Surveillance (NHBS) system, Denver Public Health has provided testing for the hepatitis C virus during several cycles. Sharing contaminated needles, syringes, and other equipment used to prepare and inject drugs can transmit hepatitis C and other blood borne infections, such as HIV and hepatitis B.

Testing using blood from a finger stick with the OraQuick® HCV Rapid Antibody test was offered to NHBS participants during the most recent rounds of data collection in 2014, 2015, and 2016.

HCV antibody status, awareness, and treatment history among NHBS participants


MSM (2014 IDU (2015) HET (2016
HCV anitbody + 2% (11/455) 60% (344/577) 9% (44/471)
Aware of infection 91% (10/11) 79% (271/344) 86% (38/44)
Ever taken HCV medication 50% (5/10) 11% (29/271) 45% (17/38)

 

Living with both HIV and HCV

HCV antibody status by HIV antibody status among gay, bisexual, and other men who have sex wtih men. (NHBS-MSM4), 2014


HIV + HIV - Total
HCV antibody + 3 (5%) 8 (2%) 11 (2%)
HCV antibody -  62 (95%) 407 (98%) 469 (98%)
Total 65 (14%) 415 (86%) 480 (100%)

Note: Oraquick HCV test used on blood draw to test for HCV antibody, Clearview Complete rapid test used on blood draw tot est for HIV.

 

HCV antibody status among persons who inject drugs (NHBS-IDU4), 2015.


HIV + HIV - Total
HCV antibody + 11 (52%) 331 (60%) 342 (60%)
HCV antibody - 10 (48%) 219 (40%) 229 (40%)
Total 21 (4%) 550 (96%) 571 (100%)

Note: Oraquick HCV test used on finger stick to test for HCV antibody, Clearview Complete rapid test used on finger stick to test for HIV.